Max Rosett Sells 14,380 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 14,380 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Immunome Trading Down 2.0 %

IMNM traded down $0.30 during trading hours on Friday, hitting $14.99. The company’s stock had a trading volume of 1,948,571 shares, compared to its average volume of 783,200. The company has a 50-day simple moving average of $14.51 and a 200 day simple moving average of $16.24. The firm has a market capitalization of $898.94 million, a PE ratio of -1.99 and a beta of 1.77. Immunome, Inc. has a fifty-two week low of $6.65 and a fifty-two week high of $30.96.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.62 million. Research analysts expect that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on IMNM shares. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Tuesday, August 13th. Piper Sandler lowered their price target on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $29.00.

Hedge Funds Weigh In On Immunome

Several large investors have recently bought and sold shares of IMNM. Avidity Partners Management LP bought a new stake in shares of Immunome in the 4th quarter worth $14,268,000. Mayo Clinic bought a new stake in Immunome in the fourth quarter worth about $1,161,000. Lord Abbett & CO. LLC bought a new stake in Immunome in the first quarter worth about $10,994,000. Swiss National Bank bought a new position in shares of Immunome during the 1st quarter valued at about $1,762,000. Finally, Sofinnova Investments Inc. boosted its position in shares of Immunome by 10.3% during the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock valued at $7,934,000 after purchasing an additional 61,284 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.